Small molecule probes that target Abl kinase.
نویسندگان
چکیده
Two different strategies, namely a dialdehyde-based cross-linking and photo-affinity labeling, have been developed to generate small molecule activity-based probes (ABPs) for the Abelson (Abl) tyrosine kinase, of which probe 13, derived from the photo-affinity approach, showed specific labeling of Abl kinase present in a crude mammalian proteome.
منابع مشابه
Fluorescence Polarization Screening Assays for Small Molecule Allosteric Modulators of ABL Kinase Function
The ABL protein-tyrosine kinase regulates intracellular signaling pathways controlling diverse cellular processes and contributes to several forms of cancer. The kinase activity of ABL is repressed by intramolecular interactions involving its regulatory Ncap, SH3 and SH2 domains. Small molecules that allosterically regulate ABL kinase activity through its non-catalytic domains may represent sel...
متن کاملA bead-based activity screen for small-molecule inhibitors of signal transduction in chronic myelogenous leukemia cells.
Chronic myelogenous leukemia is characterized by the presence of the chimeric BCR-ABL gene, which is expressed as the constitutively active Bcr-Abl kinase. Although kinase activity is directly responsible for the clinical phenotype, current diagnostic and prognostic methods focus on a genetic classification system in which molecularly distinct subcategories are used to predict patient responses...
متن کاملCrystal structures of the kinase domain of c-Abl in complex with the small molecule inhibitors PD173955 and imatinib (STI-571).
The inadvertent fusion of the bcr gene with the abl gene results in a constitutively active tyrosine kinase (Bcr-Abl) that transforms cells and causes chronic myelogenous leukemia. Small molecule inhibitors of Bcr-Abl that bind to the kinase domain can be used to treat chronic myelogenous leukemia. We report crystal structures of the kinase domain of Abl in complex with two such inhibitors, ima...
متن کاملCancer cocktails: ABL001 – hitting one target twice
Medicines [2] ABL001 is a small molecule designed to inhibit BCR-ABL, the same protein hit by imatinib and nilotinib, which are used to treat chronic myelogenous leukemia. But ABL001 has a different mechanism of action. It doesn’t bind the active site of its target. Instead it binds a different region of BCR-ABL, forcing a conformational change that disables the protein’s active site. According...
متن کاملIdentification of Small Molecules that Disrupt Signaling between ABL and Its Positive Regulator RIN1
Constitutively active BCR-ABL kinase fusions are causative mutations in the pathogenesis of hematopoietic neoplasias including chronic myelogenous leukemia (CML). Although these fusions have been successfully targeted with kinase inhibitors, drug-resistance and relapse continue to limit long-term survival, highlighting the need for continued innovative drug discovery. We developed a time-resolv...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
عنوان ژورنال:
- Chemical communications
دوره 46 7 شماره
صفحات -
تاریخ انتشار 2010